RCS - Arecor Therapeutics - TETRIS PHARMA LAUNCHES OGLUO® IN AUSTRIA

Arecor TherapeuticsAnnouncement

04/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230104:nRSD5713La&default-theme=true

RNS Number : 5713L  Arecor Therapeutics PLC  04 January 2023

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

 

TETRIS PHARMA LAUNCHES OGLUO® IN AUSTRIA

 

Cambridge, UK, 4 January 2023: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company advancing today's therapies to enable healthier
lives, announces that subsidiary company, Tetris Pharma Ltd, has today
launched Ogluo® (glucagon prefilled autoinjector pen) as a treatment for
severe hypoglycaemia in children and adults living with diabetes in Austria,
the second European launch in the Ogluo® European roll-out strategy.

 

See full Tetris Pharma announcement below:

 

Tetris Pharma European roll-out of Ogluo® continues with launch in Austria

 

A new treatment option for severe hypoglycaemia for children and adults living
with diabetes

 

 

4 January 2023 - Tetris Pharma Ltd ("Tetris Pharma" or "the Company"), a
subsidiary of biopharmaceutical company, Arecor Therapeutics plc (AIM: AREC),
today announces the launch of Ogluo® (glucagon prefilled autoinjector pen) in
Austria as a treatment for severe hypoglycaemia in adults, adolescent, and
children aged two years and over living with diabetes mellitus.

 

Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon to treat
severe hypoglyceamia for people living with diabetes. There are an estimated
450,000 adults living with diabetes in Austria (IDF Atlas 10(th) Edition).

 

Ogluo® pricing has been published in Austria in the Warenverzeichnis (the
reference for all Austrian pharmacies, insurers and wholesalers) managed by
the Apotheker-Verlages®. Full prescribing information can be found here
(https://ogluo.info/) . Today's launch in Austria builds on the roll-out of
Ogluo® in Germany and Great Britain, as part of the pan-European
commercialisation programme through which Tetris Pharma intends to
commercialise Ogluo® in core European markets. The Company is currently in
discussions with various health authorities across Europe to ensure timely
launches in additional major European countries.

 

"In Austria, people living with diabetes will now be able to receive Ogluo®
to tackle severe hypoglycaemic events, enabling patients and those around to
them to act quickly when such an event happens," said Dr Shafiq Choudhary,
Managing Director of Tetris Pharma, "With this launch in Austria, we look
forward to expanding our reach within Europe over the coming months to bring
this new treatment to people living with diabetes."

 

Enquiries:

 

Tetris Pharma

Shafiq Choudhary            +44 (0)1628 337579

 

Notes to Editors

Tetris Pharma, a subsidiary of Arecor Therapeutics plc, is a commercial-stage
specialty pharmaceutical company with expertise in registering, marketing,
sales and the distribution of speciality hospital products across the UK and
Europe. Our experienced team has a proven history of building and growing
sales. Having secured distribution rights for already licensed products across
Europe, we have a portfolio of niche injectable products including Ogluo(®),
a ready-to-use glucagon for emergency use to treat hypoglycaemia. We
collaborate with partners to provide patients with effective treatments and
quality healthcare by ensuring we deliver accountability, partnership and
performance.

 

For further information, please visit tetrispharma.com
(http://tetrispharma.com)

 

-ENDS-

 

For more information, please contact:

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications               Tel: +44 (0) 20 3709 5700

 Chris Gardner, David Daley, Angela Gray          Email: arecor@consilium-comms.com

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABJMRTMTJMBIJ